Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed newly diagnosed squamous cell carcinoma of the head and neck~  * Stage III or IV disease~ * Unresectable disease~* Unidimensionally or bidimensionally measurable disease~* Skin and tumor material must be available for EGFR status and downstream signaling studies~* No nasopharyngeal, nasal, or paranasal cancer~* No distant metastases~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times the upper limit of normal (ULN)~* Alkaline phosphatase and transaminases ≤ 2.5 times ULN~* Serum creatinine ≤ 120 μmol/L (1.36 mg/dL)~* Creatinine clearance ≥ 60 mL/min~* Normal cardiac function (i.e., LVEF ≥ 50%)~* Clinically satisfactory 12-lead ECG~* No serious cardiac illness or medical condition within the past 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No current malignancies at other sites with the exception of cone-biopsied carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma or other cancer from which the patient has been disease-free for at least the past five years~* No unstable systemic diseases~* No active uncontrolled infections~* No psychological, familial, sociological, or geographical condition that would preclude compliance with the study protocol and follow-up schedule~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior treatment for head and neck cancer~* No other concurrent anticancer therapy~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).